SUSAN WIGGSHODGE: Open Payments
NPI 1982320511 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$405 in 25 payments from 9 companies in 2025. Trend: 2023 $190 · 2024 $364 · 2025 $405
Food & beverage: $405
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $138 |
| PFIZER INC. | 6 | $97 |
| Novo Nordisk Inc | 3 | $44 |
| Astellas Pharma US Inc | 2 | $41 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
| Amgen Inc. | 1 | $15 |
| Exact Sciences Corporation | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 2 | $14 |
Products named: QULIPTA, VRAYLAR, NURTEC ODT, ELIQUIS, Veozah, GVOKE HYPOPEN, AIRSUPRA, Ozempic.
Industry payments across FL — which companies pay providers there.
